TSP Capital Management Group LLC Has $5.64 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

TSP Capital Management Group LLC lessened its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,343 shares of the biopharmaceutical company’s stock after selling 24,477 shares during the period. Celldex Therapeutics comprises 1.9% of TSP Capital Management Group LLC’s holdings, making the stock its 21st largest holding. TSP Capital Management Group LLC owned 0.34% of Celldex Therapeutics worth $5,644,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. KBC Group NV grew its position in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its position in shares of Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after purchasing an additional 2,070 shares in the last quarter. Values First Advisors Inc. grew its position in shares of Celldex Therapeutics by 13.4% during the 3rd quarter. Values First Advisors Inc. now owns 24,172 shares of the biopharmaceutical company’s stock worth $822,000 after purchasing an additional 2,853 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Celldex Therapeutics by 11.5% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company’s stock worth $1,038,000 after acquiring an additional 3,146 shares during the period.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, UBS Group began coverage on shares of Celldex Therapeutics in a report on Thursday. They set a “buy” rating and a $44.00 price target for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.22.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $23.06 on Friday. The firm has a 50 day simple moving average of $24.85 and a 200 day simple moving average of $30.03. Celldex Therapeutics, Inc. has a one year low of $20.91 and a one year high of $53.18.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.